Masayuki Takeda1, Osamu Nishizawa1, Takeshi Imaoka1, Yoji Morisaki1, Lars Viktrup1. 1. Department of Urology, Interdisciplinary Graduate School of Medicine and Engineering, University of Yamanashi, Chuo, JapanDepartment of Urology, Shinshu University School of Medicine, Matsumoto, JapanLilly Research Laboratories Japan, Eli Lilly Japan K.K., Kobe, JapanLilly Research Laboratories, Eli Lilly and Co., Indianapolis, USA.
Abstract
OBJECTIVES: To examine the efficacy, safety, and dose response of tadalafil once daily in Japanese men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (BPH-LUTS). METHODS:Men ≥45 years with moderate-to-severe BPH-LUTS were randomized to once-daily placebo (N = 140), tadalafil 2.5 mg (N = 142), or tadalafil 5.0 mg (N = 140), in a 12-week double-blind phase, followed by a 42-week, tadalafil 5.0 mg open-label extension (OLE) phase (N = 394). The primary outcome was total International Prostate Symptom Score (IPSS) change from baseline to last available observation in the double-blind phase. RESULTS: The least squares (LS) mean difference between placebo and tadalafil in total IPSS change from baseline was -0.7 (P = 0.201) and -1.1 (P = 0.062) for tadalafil 2.5 and 5 mg, respectively (ANCOVA; a dose-dependent improvement in placebo-adjusted total IPSS for tadalafil 5 mg versus 2.5 mg of 57%). Repeated-measures analyses identified a significant total IPSS change for tadalafil 5 mg (LS mean difference between placebo and tadalafil 5 mg: -1.2; P = 0.035), but not tadalafil 2.5 mg, at week 12. Significant improvements for tadalafil 5 mg were demonstrated (ANCOVA) for IPSS obstructive subscore (P = 0.033) and IPSS quality of life index (P = 0.022). Numerical improvements in IPSS scores were maintained over the OLE phase. Tadalafil was well tolerated with no unexpected adverse events. CONCLUSION:Tadalafil (5.0 mg) had a favorable benefit-to-risk profile, supporting further investigation of tadalafil (5.0 mg) in Japanese men with BPH-LUTS.
RCT Entities:
OBJECTIVES: To examine the efficacy, safety, and dose response of tadalafil once daily in Japanese men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (BPH-LUTS). METHODS:Men ≥45 years with moderate-to-severe BPH-LUTS were randomized to once-daily placebo (N = 140), tadalafil 2.5 mg (N = 142), or tadalafil 5.0 mg (N = 140), in a 12-week double-blind phase, followed by a 42-week, tadalafil 5.0 mg open-label extension (OLE) phase (N = 394). The primary outcome was total International Prostate Symptom Score (IPSS) change from baseline to last available observation in the double-blind phase. RESULTS: The least squares (LS) mean difference between placebo and tadalafil in total IPSS change from baseline was -0.7 (P = 0.201) and -1.1 (P = 0.062) for tadalafil 2.5 and 5 mg, respectively (ANCOVA; a dose-dependent improvement in placebo-adjusted total IPSS for tadalafil 5 mg versus 2.5 mg of 57%). Repeated-measures analyses identified a significant total IPSS change for tadalafil 5 mg (LS mean difference between placebo and tadalafil 5 mg: -1.2; P = 0.035), but not tadalafil 2.5 mg, at week 12. Significant improvements for tadalafil 5 mg were demonstrated (ANCOVA) for IPSS obstructive subscore (P = 0.033) and IPSS quality of life index (P = 0.022). Numerical improvements in IPSS scores were maintained over the OLE phase. Tadalafil was well tolerated with no unexpected adverse events. CONCLUSION:Tadalafil (5.0 mg) had a favorable benefit-to-risk profile, supporting further investigation of tadalafil (5.0 mg) in Japanese men with BPH-LUTS.
Authors: Philipp Dahm; Michelle Brasure; Roderick MacDonald; Carin M Olson; Victoria A Nelson; Howard A Fink; Bruce Rwabasonga; Michael C Risk; Timothy J Wilt Journal: Eur Urol Date: 2016-10-04 Impact factor: 20.096
Authors: Hyun Jun Park; Ji Eon Joanne Won; Sebastian Sorsaburu; Paul David Rivera; Seung Wook Lee Journal: World J Mens Health Date: 2013-12-24 Impact factor: 5.400
Authors: Ji Eon Won; Ji Yeon Chu; Hyunah Caroline Choi; Yun Chen; Hyun Jun Park; Héctor José Dueñas Journal: World J Mens Health Date: 2017-09-06 Impact factor: 5.400
Authors: Smita Pattanaik; Ravimohan S Mavuduru; Arabind Panda; Joseph L Mathew; Mayank M Agarwal; Eu Chang Hwang; Jennifer A Lyon; Shrawan K Singh; Arup K Mandal Journal: Cochrane Database Syst Rev Date: 2018-11-16
Authors: Sung Won Lee; Jae Seung Paick; Hyun Jun Park; Ji Eon Won; Yoji Morisaki; Sebastian Sorsaburu; Lars Viktrup Journal: World J Mens Health Date: 2014-04-25 Impact factor: 5.400
Authors: A Sebastianelli; P Spatafora; S Morselli; L Vignozzi; S Serni; K T McVary; S Kaplan; S Gravas; C Chapple; Mauro Gacci Journal: Curr Urol Rep Date: 2020-10-27 Impact factor: 3.092